Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

Autor: Mosele, M.F., Westphalen, C.B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., Czarnecka, A.M., Meric-Bernstam, F., Michiels, S., Miller, R., Normanno, N., Reis-Filho, J., Remon, J., Robson, M., Rouleau, E., Scarpa, A., Serrano, C., Mateo, J., André, F.

Publikováno v: In Annals of Oncology July 2024 35(7):588-606

ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe

Autor: Bayle, A., Bonastre, J., Chaltiel, D., Latino, N., Rouleau, E., Peters, S., Galotti, M., Bricalli, G., Besse, B., Giuliani, R.

Publikováno v: In Annals of Oncology October 2023 34(10):934-945

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial

Autor: Le Cesne, A., Blay, J.-Y., Cupissol, D., Italiano, A., Delcambre, C., Penel, N., Isambert, N., Chevreau, C., Bompas, E., Bertucci, F., Chaigneau, L., Piperno-Neumann, S., Salas, S., Rios, M., Guillemet, C., Bay, J.-O., Ray-Coquard, I., Haddag, L., Bonastre, J., Kapso, R., Fraslin, A., Bouvet, N., Mir, O., Foulon, S.

Publikováno v: In Annals of Oncology August 2021 32(8):1034-1044

Reply to the Letter to the Editor regarding 'Overcoming Barriers in Biomarker Testing' J. García-Foncillas et al.

Autor: Bayle A; Bureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif; INSERM, Université Paris-Saclay, CESP U1018 Oncostat, Labelisé Ligue Contre le Cancer, Villejuif, France; European Society for Medical Oncology (ESMO), Lugano, Switzerland. Electronic address: arnaud.bayle@gustaveroussy.fr., Chaltiel D; Bureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif; INSERM, Université Paris-Saclay, CESP U1018 Oncostat, Labelisé Ligue Contre le Cancer, Villejuif, France., Latino N; European Society for Medical Oncology (ESMO), Lugano, Switzerland., Rouleau E; Department of Medical Biology and Pathology, Tumor Genetic Lab, Gustave Roussy, Villejuif; INSERM UMR 981, Gustave Roussy, Villejuif, France., Peters S; European Society for Medical Oncology (ESMO), Lugano, Switzerland; Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Galotti M; European Society for Medical Oncology (ESMO), Lugano, Switzerland., Bricalli G; European Society for Medical Oncology (ESMO), Lugano, Switzerland., Besse B; Faculté de Médicine, Université Paris-Saclay, Université Paris-Sud, Paris; Department of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, France., Giuliani R; European Society for Medical Oncology (ESMO), Lugano, Switzerland; Guy's and St Thomas NHS Foundation Trust, London, UK., Bonastre J; Bureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif; INSERM, Université Paris-Saclay, CESP U1018 Oncostat, Labelisé Ligue Contre le Cancer, Villejuif, France.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Sep; Vol. 35 (9), pp. 829-830. Date of Electronic Publication: 2024 Jun 06.

Sources de données, données utilisées et modalité de recueil

Autor: Baffert, S., Bertaux, A.-C., Bonastre, J., Costa, N., Deniès, F., Dervaux, B., Dutot, C., Guerre, P., Havet, N., Hayes, N., Le Corroller-Soriano, A.-G., Lejeune, C., Lueza, B., Margier, J., Mercier, G., Morelle, M., Perrier, L., Pagès, A., Plantier, M., Riche, V.-P.

Publikováno v: In Revue d'Epidemiologie et de Santé Publique March 2018 66 Supplement 2:S73-S91